In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens.
CITATION STYLE
Firestone, R., Lesokhin, A. M., & Usmani, S. Z. (2023). An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma. Blood Cancer Discovery, 4(6), 433–436. https://doi.org/10.1158/2643-3230.BCD-23-0176
Mendeley helps you to discover research relevant for your work.